ID

42562

Description

Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98; ODM derived from: https://clinicaltrials.gov/show/NCT00899288

Link

https://clinicaltrials.gov/show/NCT00899288

Keywords

Versions (2)
  1. 1/19/17 1/19/17 -
  2. 9/2/21 9/2/21 -
Uploaded on

September 2, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Breast Cancer NCT00899288

English

Eligibility Breast Cancer NCT00899288

1 forms  
Criteria
Description

Criteria

enrolled on protocol ibcsg-1-98
Description

Enrollment

Data type

boolean

Alias
UMLS CUI [1]
C1516879
currently receiving (i.e., have not yet completed) 5 years of treatment with tamoxifen or letrozole and expected to receive ≥ 6 months of additional treatment on protocol ibcsg-1-98
Description

Tamoxifen | letrozole | Additional Therapy Expected

Data type

boolean

Alias
UMLS CUI [1]
C0039286
UMLS CUI [2]
C0246421
UMLS CUI [3,1]
C1706712
UMLS CUI [3,2]
C1517001
no recurrent breast cancer or second primary cancer
Description

Breast cancer recurrent | Second Primary Cancers

Data type

boolean

Alias
UMLS CUI [1]
C0278493
UMLS CUI [2]
C0751623
no known bone disease (including osteomalacia or osteogenesis imperfecta)
Description

Bone Diseases | Osteomalacia | Osteogenesis Imperfecta

Data type

boolean

Alias
UMLS CUI [1]
C0005940
UMLS CUI [2]
C0029442
UMLS CUI [3]
C0029434
hormone receptor status
Description

Hormone Receptor Status

Data type

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C0449438
estrogen and/or progesterone receptor positive tumor
Description

Estrogen receptor positive tumor | Progesterone receptor positive tumor

Data type

boolean

Alias
UMLS CUI [1]
C1562312
UMLS CUI [2]
C1562928
patient characteristics:
Description

Client Characteristics

Data type

boolean

Alias
UMLS CUI [1]
C0815172
female
Description

Gender

Data type

boolean

Alias
UMLS CUI [1]
C0079399
postmenopausal
Description

Postmenopausal state

Data type

boolean

Alias
UMLS CUI [1]
C0232970
no uncontrolled thyroid or parathyroid disease, cushing's disease, or other pituitary diseases
Description

Thyroid Disease Uncontrolled | Parathyroid Disease Uncontrolled | Cushing's disease | Pituitary Diseases

Data type

boolean

Alias
UMLS CUI [1,1]
C0040128
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0030517
UMLS CUI [2,2]
C0205318
UMLS CUI [3]
C0221406
UMLS CUI [4]
C0032002
no malabsorption syndrome or clinically relevant vitamin d deficiency
Description

Malabsorption Syndrome | Vitamin D Deficiency Relevant Clinical

Data type

boolean

Alias
UMLS CUI [1]
C0024523
UMLS CUI [2,1]
C0042870
UMLS CUI [2,2]
C2347946
UMLS CUI [2,3]
C0205210
prior concurrent therapy:
Description

Therapeutic procedure

Data type

boolean

Alias
UMLS CUI [1]
C0087111
see disease characteristics
Description

disease characteristic

Data type

boolean

Alias
UMLS CUI [1]
C0599878
more than 1 year since prior and no concurrent anticonvulsants
Description

Anticonvulsants

Data type

boolean

Alias
UMLS CUI [1]
C0003286
more than 6 months since prior and no concurrent corticosteroids at doses > the equivalent of 5 mg/day of prednisone for > 2 weeks total
Description

Adrenal Cortex Hormones Dose | Prednisone U/day

Data type

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C0178602
UMLS CUI [2,1]
C0032952
UMLS CUI [2,2]
C0456683
no prior or concurrent sodium fluoride at daily doses ≥ 5 mg/day for > 1 month
Description

Sodium Fluoride Dose U/day

Data type

boolean

Alias
UMLS CUI [1,1]
C0037508
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0456683
more than 12 months since prior and no concurrent anabolic steroids
Description

Anabolic steroids

Data type

boolean

Alias
UMLS CUI [1]
C0002845
more than 6 months since any prior drug for the prevention of osteoporosis (excluding calcium or cholecalciferol [vitamin d])
Description

Pharmaceutical Preparations Prevention Osteoporosis | Calcium | Cholecalciferol | Vitamin D

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C2700409
UMLS CUI [1,3]
C0029456
UMLS CUI [2]
C0006675
UMLS CUI [3]
C0008318
UMLS CUI [4]
C0042866
concurrent warfarin allowed provided duration of treatment is no more than 4 weeks
Description

Warfarin

Data type

boolean

Alias
UMLS CUI [1]
C0043031
Back to the top of the page

Similar models

Eligibility Breast Cancer NCT00899288

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Enrollment
Item
enrolled on protocol ibcsg-1-98
boolean
C1516879 (UMLS CUI [1])
Tamoxifen | letrozole | Additional Therapy Expected
Item
currently receiving (i.e., have not yet completed) 5 years of treatment with tamoxifen or letrozole and expected to receive ≥ 6 months of additional treatment on protocol ibcsg-1-98
boolean
C0039286 (UMLS CUI [1])
C0246421 (UMLS CUI [2])
C1706712 (UMLS CUI [3,1])
C1517001 (UMLS CUI [3,2])
Breast cancer recurrent | Second Primary Cancers
Item
no recurrent breast cancer or second primary cancer
boolean
C0278493 (UMLS CUI [1])
C0751623 (UMLS CUI [2])
Bone Diseases | Osteomalacia | Osteogenesis Imperfecta
Item
no known bone disease (including osteomalacia or osteogenesis imperfecta)
boolean
C0005940 (UMLS CUI [1])
C0029442 (UMLS CUI [2])
C0029434 (UMLS CUI [3])
Hormone Receptor Status
Item
hormone receptor status
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
Estrogen receptor positive tumor | Progesterone receptor positive tumor
Item
estrogen and/or progesterone receptor positive tumor
boolean
C1562312 (UMLS CUI [1])
C1562928 (UMLS CUI [2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Postmenopausal state
Item
postmenopausal
boolean
C0232970 (UMLS CUI [1])
Thyroid Disease Uncontrolled | Parathyroid Disease Uncontrolled | Cushing's disease | Pituitary Diseases
Item
no uncontrolled thyroid or parathyroid disease, cushing's disease, or other pituitary diseases
boolean
C0040128 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0030517 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0221406 (UMLS CUI [3])
C0032002 (UMLS CUI [4])
Malabsorption Syndrome | Vitamin D Deficiency Relevant Clinical
Item
no malabsorption syndrome or clinically relevant vitamin d deficiency
boolean
C0024523 (UMLS CUI [1])
C0042870 (UMLS CUI [2,1])
C2347946 (UMLS CUI [2,2])
C0205210 (UMLS CUI [2,3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
disease characteristic
Item
see disease characteristics
boolean
C0599878 (UMLS CUI [1])
Anticonvulsants
Item
more than 1 year since prior and no concurrent anticonvulsants
boolean
C0003286 (UMLS CUI [1])
Adrenal Cortex Hormones Dose | Prednisone U/day
Item
more than 6 months since prior and no concurrent corticosteroids at doses > the equivalent of 5 mg/day of prednisone for > 2 weeks total
boolean
C0001617 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0032952 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
Sodium Fluoride Dose U/day
Item
no prior or concurrent sodium fluoride at daily doses ≥ 5 mg/day for > 1 month
boolean
C0037508 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
Anabolic steroids
Item
more than 12 months since prior and no concurrent anabolic steroids
boolean
C0002845 (UMLS CUI [1])
Pharmaceutical Preparations Prevention Osteoporosis | Calcium | Cholecalciferol | Vitamin D
Item
more than 6 months since any prior drug for the prevention of osteoporosis (excluding calcium or cholecalciferol [vitamin d])
boolean
C0013227 (UMLS CUI [1,1])
C2700409 (UMLS CUI [1,2])
C0029456 (UMLS CUI [1,3])
C0006675 (UMLS CUI [2])
C0008318 (UMLS CUI [3])
C0042866 (UMLS CUI [4])
Warfarin
Item
concurrent warfarin allowed provided duration of treatment is no more than 4 weeks
boolean
C0043031 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial